Effects of interferon therapy in "non responder" patients with chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 178-183

  Poynard, T ^a   Moussali, J ^a   Ratziu, V ^a   Regimbeau, C ^a   Opolon, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

"non responders"; HCV; Histological features; Interferon; Transaminase serum activity; Viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; PRIORITY JOURNAL; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER NEOPLASMS; TREATMENT FAILURE; VIRAL LOAD;

EID: 0033428746     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80397-3     Document Type: Article

References (43)

1. Hoofnagle JH, Müllen KD, Brian Jones D et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986: 315: 1575-1578.
2. Poynard T, Lêroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996: 24: 778-789
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998: 352: 1426-1432.
4. Me Hutchison JG, Gordon SC, Schiff ER et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
5. Poynard T. Interferon alpha in hepatitis C: a cytokine for reducing fibrosis progression. Eur Cytokine Network 1997: 8: 319-320.
6. Peters M. Actions of cytokines on the immune response and viral interactions: An overview. Hepatology 1996: 23: 909-916.
7. Shindo M, Di Bisceglie A, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991: 115: 700-704.
8. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alpha 2b regimens for long term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995: 332: 1457-1462.
9. Lau J, Mizokami M, Ohno T, Diamond D, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993: 342: 12081209.
10. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks. Hepatology 1994: 19: 280-285.
11. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993: 104: 877-883.
12. Manabe N, Chevalier M, Chossegros P, Causse X, Guerret S, Trepo C et al. Interferon-a2b therapy reduces liver fibrosis in chronic non-A-non-B hepatitis: a quantitative histological evaluation. Hepatology 1993: 18: 1344-1349.
13. Castilla A, Prieto J, Fausto N. Transforming growth factor B1 and a in chronic liver disease: effect of interferon alpha therapy. N Engl J Med 1991: 324: 933-940.
14. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long term decrease in serum N terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alpha. Hepatology 1995: 22: 426-131.
15. Pilette C, Fort J, Riflet H, Cales P. Anti-fibrotic effects of interferons. Mechanisms and therapeutic prospects. Gastroenterol Clin Biol 1997: 21: 466-471.
16. Hiramatsu N, Hayashi N, Kasahara A. Improvement of liver fibrosis in chronic viral hepatitis C patients with natural interferon alpha. J Hepatol 1995: 22: 135-142.
17. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995: 21: 1003-1010.
18. Craig JR, Bain VG, Ehrinpreis M et al. Liver histology improves in both cirrhotic and non cirrhotic patients with chronic HCV infection following consensus interferon therapy (Abstract). Gastroenterology 1997: 112: A 1248.
19. Jensen D, Shafritz D, Craig JR et al. Nonresponders to CIFN show clinically relevant improvements in liver histology (Abstract). Gastroenterology 1997: 112: A 1294.
20. Degos F, Daurat V, Chevret S et al. Reinforced regimen of interferon alpha 2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicenter randomized trial. J Hepatol 1998: 29: 224-232.
21. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997: 26: 1187-1199.
22. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997: 349: 825-832.
23. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M et al. for the MULTIVIRC group. Modeling the impact of alpha interferon treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999: 116: 378-386.
24. Poynard T, McHutchison J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P et al. for the FIBROVIRC Project Group. Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 1998: 28: 497A.
25. Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment ? Hepatology 1998: in press.
26. Physician's desk reference. Medical Economics, 49th edn. Montvale, NJ: 1995. p. 2266.
27. Vidai 1995. 71st edn. Paris: Editions Vidai: 1995. p. 757.
28. Jury. Hépatite C: dépistage et traitement. Conférence de consensus. Conclusions et recommandations du Jury. Texte long. Gastroenterol Clin Biol 1997: 20: S202-S211.
29. National Institutes of Health consensus development conference panel statement: management of hepatitis C. Hepatology 1997: 26 (Suppl 1): 2S-10S.
30. Royal College of Physicians and British Society of Gastroenterology. Clinical guidelines on the use of alpha interferon in the treatment of hepatitis C: 1998: In press.
31. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997: 350: 1425-1431.
32. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer [letter]. Lancet 1998: 351: 214-215.
33. Poynard T, Moussalli J, Ratziu V, Thévenot T, Regimbeau C, Opolon P. Treatment of patients with cirrhosis due to hepatitis C by interferon or ribavirin: Pro. Acta Belg Gastroenterol 1999: in press.
34. Cooksley WGE. Interferon treatment of chronic hepatitis C with cirrhosis. J Viral Hepatitis 1997: 4 (Suppl): 85-88.
35. Idilman R, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepatitis 1997: 4: 81-91.
36. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Stat Med 1987: 6: 341-348.
37. Der Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986: 7: 177-188.
38. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995: 346: 1051-1055.
39. Valla D, Chevallier M, Payen JL, Marcellin P, Parlier D, Trepo C et al. Essai thérapeutique contrôlé de l'interféron cr2b chez les patients atteints de cirrhose virale C. Gastroenterol Clin Biol 1997: 21: 704 (abstract).
40. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 1998: 27: 1435-1440.
41. International Interferon-Hepatocellular Carcinoma Study Group. Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998: 351: 1535-1539.
42. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Albert! A et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998: 83: 901-909.
43. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996: Feb. 24 (2): 141-147.